Imtiaz Islam, MD
Nephrology · Kearney, NENPI 1336122597
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,377 of the $2,665 with a category attached, or 89.2%. It is spread thinly across 30 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 162 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$399
- Fresenius USA Marketing, Inc.$295
- Travere Therapeutics, Inc.$287
- AstraZeneca$210
- Vifor Pharma, Inc.$202
- Mallinckrodt Hospital Products Inc.$153
- plus $1K from 24 others
What the payments were for
- Consulting fees$763%
- Food & beverage$2,37789%
- Education$2128%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $399 |
| Fresenius USA Marketing, Inc. | 20 | $295 |
| Travere Therapeutics, Inc. | 33 | $287 |
| AstraZeneca(2 entities) | 15 | $210 |
| Vifor Pharma, Inc. | 8 | $202 |
| Mallinckrodt Hospital Products Inc. | 4 | $153 |
| Aurinia Pharma U.S., Inc. | 4 | $149 |
| Otsuka America Pharmaceutical, Inc. | 9 | $140 |
| Pfizer | 2 | $111 |
| Johnson & Johnson(2 entities) | 4 | $80 |
| Biomerieux Inc | 1 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Novartis | 4 | $65 |
| Calliditas Therapeutics US Inc. | 3 | $59 |
| Novo Nordisk | 4 | $54 |
| Bayer | 2 | $35 |
| Scpharmaceuticals Inc. | 2 | $32 |
| GSK | 2 | $32 |
| Gilead | 1 | $30 |
| Medtronic | 1 | $27 |
| Lilly USA, LLC | 2 | $25 |
| Ardelyx, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi | 1 | $14 |
| AbbVie | 1 | $13 |
| Angiodynamics, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$100
How this compares
$2,665 in reported general payments places this provider in the 65th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 28 | $523,364 |
| JardianceEmpagliflozin | 152 | $105,224 |
| FarxigaDapagliflozin Propanediol | 151 | $100,703 |
| VelphoroSucroferric Oxyhydroxide | 28 | $80,275 |
| XphozahTenapanor Hcl | 15 | $57,440 |
| LokelmaSodium Zirconium Cyclosilicate | 50 | $53,473 |
| Sevelamer Carbonate | 195 | $31,534 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $26,938 |
| KerendiaFinerenone | 37 | $22,972 |
| Cinacalcet Hcl | 28 | $21,802 |
| RenvelaSevelamer Carbonate | 16 | $21,187 |
| Telmisartan | 263 | $8,800 |
| EliquisApixaban | 12 | $7,032 |
| Potassium Chloride | 216 | $5,435 |
| Midodrine Hcl | 106 | $5,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $140 | $523,36428 claims |
| AstraZenecaFarxiga, Lokelma | $210 | $154,176201 claims |
| Fresenius USA Marketing, Inc.Velphoro | $295 | $80,27528 claims |
| BayerKerendia | $35 | $22,97237 claims |
| PfizerEliquis | $111 | $7,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Kearney
- Abhisekh Sinha RayKearney$2K
- Michael AaronsonLincoln$498K
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Rachel BrockLincoln$87K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.